Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Oncolytics Biotech ( (TSE:ONC) ).
Oncolytics Biotech has announced significant clinical data for pelareorep, demonstrating strong survival benefits in metastatic pancreatic ductal adenocarcinoma and HR+/HER2- metastatic breast cancer. The data highlights a two-year survival rate of 21.9% in pancreatic cancer, compared to a historical benchmark of 9.2%, and a median overall survival benefit of over 10 months in breast cancer compared to standard chemotherapy. These results underscore pelareorep’s potential to transform treatment in cancers that are typically unresponsive to immunotherapies, positioning Oncolytics as a leader in the oncology immunotherapy space. The company plans to leverage its fast-track status to expedite regulatory pathways for pelareorep’s advancement.
The most recent analyst rating on (TSE:ONC) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the TSE:ONC Stock Forecast page.
Spark’s Take on TSE:ONC Stock
According to Spark, TipRanks’ AI Analyst, TSE:ONC is a Neutral.
Oncolytics Biotech faces significant financial challenges with persistent operational losses and reliance on external funding. Although technical indicators suggest bearish momentum, clinical advancements in cancer treatments provide some optimism. The valuation reflects the speculative nature of biotech investments, with no revenue and negative P/E. Recent earnings call and corporate events offer potential upside through strategic developments but are overshadowed by leadership transitions and market value concerns. Overall, the stock remains speculative with potential upside contingent on successful clinical outcomes.
To see Spark’s full report on TSE:ONC stock, click here.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage company focused on developing immunotherapy treatments for oncology. Its primary product is pelareorep, an intravenously delivered oncolytic virus immunotherapy, which targets various tumor types. The company is committed to advancing pelareorep into registration-enabling studies, particularly in challenging cancer indications such as metastatic pancreatic ductal adenocarcinoma and HR+/HER2- metastatic breast cancer.
Average Trading Volume: 155,238
Technical Sentiment Signal: Hold
Current Market Cap: C$121.7M
See more data about ONC stock on TipRanks’ Stock Analysis page.